CKD to patent an anti-sepsis drug, CKD-712 in Korea.

Chongkundang (CKD) announced on Sept. 22 that CKD-712, an antibacterial agent for the treatment of sepsis and a derivative of Tetrahydroisoquinolone compounds and its manufacturing process had completed to patent in Korea.

The active ingredient has been developed by over 3 billion won of investment for the use as an anti-sepsis drug by its cardiac muscle constriction activity, anti-coagulati...